Search
for
Sort by
Research 421–450 of 1000+
- A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
- Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women<sup>1</sup>
- 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia
- Allelic frequencies for the seventeen Y-STR loci observed in Iraqi male patients with prostate cancer
- Male breast cancer after finasteride therapy for benign prostate hyperplasia
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- QUALITY ASSESSMENT OF HERBAL MEDICINAL PRODUCTS IN BENIGN PROSTATE HYPERTROPHY: CHEMICAL MARKERS AND FINGERPRINT ANALYSIS
- Morphological Changes of Meibomian Glands in Men With Benign Prostate Hyperplasia
- Serum prostate spesific antigen levels in women with androgenetic alopecia
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
- Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
- Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt
- Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
- Redefining hormone resistance in prostate cancer
- Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
- Hormonal manipulation of benign prostatic hyperplasia
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- Risk factors for prostate cancer: a case‐control study in Greece
- Clinical and metabolic implications of obesity in prostate cancer: is testosterone a missing link?
- Recent advances in treatment for Benign Prostatic Hyperplasia
- A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
- Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
- The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
- Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth
- Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer
- Diabetes Mellitus and Prostate Cancer Risk—A Systematic Review and Meta-Analysis
- Low-Dose Dimethyl Sulfoxide (DMSO) Suppresses Androgen Receptor (AR) and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer (CRPC) Cells